stockrow
Friday 6 November 2026
Export NSPR’s income statement to Excel — free account
InspireMD, Inc.
NSPR Healthcare Medical Devices
InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024.
- Revenue
- −0.39%
- EPS
- +34.6%
- Free cash flow
- −26.0%
Quarter to June 2026, against a year earlier
0.65
0.01
+1.56%
Follow NSPR
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 2 | 6 | 4 | 5 | 4 | 2 | 5 | 5 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(2.61) | (2.78) | (1.86) | (12.39) | (4.42) | (13.42) | (24.37) | (17.11) | (35.34) | (21.22) |
P/S ratio |
12.75 | 15.73 | 10.60 | 1.40 | 4.94 | 3.11 | 0.61 | 1.03 | 0.62 | 3.27 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(10.12) | (14.33) | (7.79) | (24.92) | (6.41) | (28.20) | (54.31) | (36.17) | (80.26) | (47.68) |
Beneish M-Score |
(3.55) | (3.16) | (2.28) | (3.11) | (2.54) | (0.18) | (1.02) | (2.46) | (2.18) | (4.69) |
P/Operating CF |
(12.25) | (16.34) | (15.74) | (2.27) | (7.65) | (3.51) | (1.44) | (2.05) | (0.96) | (3.29) |
P/B ratio |
2.07 | 3.06 | 1.66 | 0.42 | 0.66 | 0.64 | 0.42 | 0.42 | 0.63 | 1.53 |
Price to Tangible BV |
2.08 | 3.06 | 1.67 | 0.42 | 0.66 | 0.64 | 0.42 | 0.42 | 0.63 | 1.55 |
EV/Sales |
7.14 | 11.33 | 4.92 | (1.31) | (1.80) | (0.46) | 0.14 | (0.53) | 0.64 | 1.30 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.37 | 0.55 | 0.11 | 0.00 | 0.26 | 0.00 | 0.00 |
EV/Operating CF |
(1.83) | (3.63) | (1.86) | 0.44 | 0.61 | 0.13 | (0.05) | 0.25 | (0.22) | (0.33) |
EV/FCF |
(1.74) | (3.41) | (1.82) | 0.42 | 0.60 | 0.12 | (0.05) | 0.25 | (0.21) | (0.33) |
Quick Ratio |
5.30 | 4.80 | 6.89 | 3.76 | 8.15 | 3.67 | 2.08 | 3.49 | 1.84 | 1.69 |
Current Ratio |
5.74 | 5.28 | 7.34 | 4.21 | 8.53 | 4.14 | 2.51 | 3.91 | 2.08 | 1.81 |
Net Debt/EBITDA |
1.10 | 1.04 | 1.87 | 0.96 | 2.34 | 1.24 | 0.57 | 1.26 | 0.46 | 0.65 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 28.48% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 |
Asset Turnover |
0.15 | 0.15 | 0.17 | 0.16 | 0.16 | 0.18 | 0.34 | 0.39 | 0.36 | 0.25 |
Operating CF/Net income |
0.72 | 0.68 | 0.82 | 0.84 | 0.89 | 0.86 | 0.98 | 1.05 | 0.62 | 0.89 |
Capex/Depreciation |
(3.46) | (5.01) | (1.59) | (2.52) | (2.14) | (0.44) | (1.80) | (0.44) | (1.45) | (0.26) |
Interest Coverage |
— | — | — | — | — | — | — | — | (69.18) | (10.61) |
| (106.88%) | (84.68%) | (70.01%) | (72.62%) | (65.29%) | (120.19%) | (141.95%) | (126.02%) | (384.76%) | (1,539.76%) | |
| (83.96%) | (67.77%) | (55.10%) | (57.46%) | (51.90%) | (76.25%) | (90.58%) | (78.72%) | (167.92%) | (112.04%) | |
ROIC |
(3,132.20%) | (1,445.09%) | (2,764.51%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(89.77%) | (90.89%) | (50.81%) | (107.67%) | (44.69%) | (87.27%) | (191.53%) | (81.17%) | (413.72%) | (199.88%) |
Average Days of Receivables |
104.39 | 117.38 | 144.24 | 88.02 | 112.79 | 138.80 | 95.44 | 83.12 | 112.37 | 106.19 |
Research and Development Expense of Revenue |
167.09% | 194.52% | 128.62% | 151.03% | 114.75% | 89.86% | 79.39% | 42.63% | 46.22% | 68.16% |
Selling, General and Administrative Expense of Revenue |
414.97% | 304.97% | 241.24% | 232.45% | 229.41% | 331.19% | 204.73% | 196.36% | 273.13% | 341.02% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
137.34% | 144.64% | 72.36% | 45.48% | 35.06% | 24.39% | 8.73% | 1.94% | 24.34% | 51.64% |
Graham Net Nets |
0.41 | 0.27 | 0.55 | 1.94 | 1.39 | 1.26 | 1.47 | 2.14 | 1.04 | 0.53 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(44.38%) | (29.66%) | (39.85%) | (254.35%) | (67.88%) | (231.78%) | (670.04%) | (782.70%) | (1,091.49%) | (613.06%) |
Free Cash Flow Yield |
(32.10%) | (21.10%) | (25.46%) | (221.14%) | (61.10%) | (119.90%) | (446.98%) | (207.60%) | (491.66%) | (121.84%) |
Revenue per Share |
0.14 | 0.17 | 0.26 | 0.66 | 0.61 | 1.64 | 26.69 | 116.92 | 5,522.00 | 34,873.87 |
Operating CF per Share |
(0.55) | (0.52) | (0.67) | (1.97) | (1.80) | (6.00) | (70.37) | (246.95) | (16,262.00) | (138,004.05) |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.06) | (0.05) | (0.04) | (2.04) | (2.18) | (516.00) | (902.23) |
Free Cash Flow per Share |
(0.57) | (0.55) | (0.69) | (2.03) | (1.85) | (6.05) | (72.41) | (249.12) | (16,778.00) | (138,906.28) |
Cash per Share |
0.84 | 0.83 | 1.61 | 2.26 | 4.63 | 8.36 | 39.56 | 304.68 | 7,420.00 | 138,390.72 |
Shareholders Equity per Share |
0.86 | 0.86 | 1.63 | 2.21 | 4.56 | 8.04 | 38.62 | 284.51 | 5,454.00 | 74,479.84 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
Book value per Share |
0.86 | 0.86 | 1.63 | 2.21 | 4.56 | 8.04 | 38.62 | 284.51 | 5,454.00 | 74,479.84 |
Free Cash Flow |
(36.75) | (23.27) | (16.74) | (16.01) | (13.55) | (9.15) | (10.09) | (7.67) | (8.39) | (7.54) |
Working Capital |
50.76 | 32.84 | 38.14 | 16.26 | 32.75 | 11.63 | 4.70 | 8.50 | 2.67 | 3.85 |
Capital Expenditures |
(1.65) | (1.40) | (0.37) | (0.47) | (0.34) | (0.07) | (0.28) | (0.07) | (0.26) | (0.05) |
Net Current Asset Value |
47.27 | 29.80 | 36.02 | 14.07 | 30.91 | 9.73 | 3.31 | 7.89 | 1.78 | 3.27 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.36 | 0.55 | 0.11 | 0.00 | 0.25 | 0.00 | 0.00 |
Capex to Sales |
0.18 | 0.20 | 0.06 | 0.09 | 0.08 | 0.03 | 0.08 | 0.02 | 0.09 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.12 | 0.22 | 0.21 | 0.25 | 0.34 | 0.29 | 0.36 | 0.37 | 0.50 |
Cash ROIC |
(33.59%) | (32.90%) | (21.32%) | (45.50%) | (20.06%) | (36.87%) | (92.63%) | (42.28%) | (130.32%) | (52.97%) |
Accounts Receivable Turnover |
3.72 | 2.98 | 3.36 | 3.92 | 3.85 | 2.59 | 4.15 | 4.31 | 3.94 | 3.45 |
Accounts Payable Turnover |
0.69 | 0.80 | 0.79 | 0.86 | 0.93 | 0.70 | 0.99 | 0.97 | 0.96 | 0.78 |
Inventory Turnover |
2.12 | 2.35 | 2.36 | 2.93 | 2.92 | 1.81 | 2.50 | 3.13 | 4.21 | 2.86 |
Average Days of Payables |
617.67 | 509.26 | 499.61 | 456.48 | 424.13 | 563.00 | 383.47 | 405.48 | 412.97 | 420.61 |
Days of Inventory on Hand |
195.82 | 170.46 | 174.78 | 145.95 | 111.52 | 215.02 | 152.16 | 158.83 | 89.40 | 101.84 |
Average Receivables |
2.41 | 2.35 | 1.85 | 1.32 | 1.17 | 0.96 | 0.90 | 0.84 | 0.70 | 0.55 |
Average Payables |
9.20 | 6.85 | 5.55 | 4.71 | 4.03 | 3.41 | 3.01 | 2.68 | 2.26 | 2.29 |
Average Inventory |
2.98 | 2.34 | 1.86 | 1.38 | 1.28 | 1.33 | 1.19 | 0.83 | 0.52 | 0.63 |
Average Assets |
58.11 | 47.23 | 36.15 | 32.18 | 28.74 | 13.83 | 11.08 | 9.20 | 7.76 | 7.55 |
Average Common Equity |
45.64 | 37.79 | 28.45 | 25.46 | 22.85 | 8.77 | 7.07 | 5.75 | 3.39 | 0.55 |
Columns are period end dates · fundamentals updated 26 Oct 2026